A 340B pharmacy is a pharmacy that dispenses medications purchased at steep discounts through the federal 340B Drug Pricing Program. Created in 1992, this program requires drug manufacturers to sell outpatient medications at reduced prices to certain healthcare organizations that serve low-income and uninsured patients. In 2024 alone, participating entities purchased $81.4 billion in discounted drugs through the program.
The term “340B pharmacy” can refer to either an in-house pharmacy operated directly by a qualifying healthcare organization or a retail pharmacy that has a contract arrangement to dispense discounted drugs on that organization’s behalf. Either way, the pharmacy is part of a system designed to help safety-net providers stretch their budgets further.
How the 340B Program Works
The basic mechanism is straightforward. Drug manufacturers that want their products covered by Medicaid are required to participate in the 340B program. That means they must offer a discounted “ceiling price” on all covered outpatient drugs to eligible healthcare organizations, known as “covered entities.” These entities then purchase medications at the lower price and dispense them to their patients, often through a pharmacy.
The discount only applies to outpatient drugs. Medications used for hospital inpatients are excluded, and participating organizations must maintain tracking systems to ensure 340B-purchased drugs aren’t diverted to inpatient use.
Here’s where the financial picture gets interesting: covered entities typically purchase drugs at the 340B discount but may dispense them to insured patients whose insurance reimburses at a higher rate. The difference between the low purchase price and the higher reimbursement generates revenue that the organization can reinvest. The original intent, as described by Congress, was to help these providers “stretch scarce federal resources as far as possible, reaching more eligible patients and providing more comprehensive services.” However, the law does not actually require that 340B savings be spent on charity care or any specific purpose.
Who Qualifies as a Covered Entity
Not every hospital or clinic can participate. The Health Resources and Services Administration (HRSA), which oversees the program, limits eligibility to specific types of organizations that serve vulnerable populations. These fall into four broad categories:
- Federally qualified health centers: community health centers, Native Hawaiian health centers, and tribal and urban Indian health centers
- Ryan White HIV/AIDS Program grantees: organizations receiving federal funding for HIV/AIDS care
- Eligible hospitals: children’s hospitals, critical access hospitals, disproportionate share hospitals (those serving a high percentage of low-income patients), free-standing cancer hospitals, rural referral centers, and sole community hospitals
- Specialized clinics: family planning clinics, sexually transmitted disease clinics, tuberculosis clinics, black lung clinics, and hemophilia treatment centers
The common thread is that these organizations either receive certain federal grants or serve a disproportionate share of patients who are uninsured, underinsured, or on Medicaid.
In-House vs. Contract Pharmacies
Some covered entities operate their own pharmacies, where patients fill prescriptions on-site. But many, particularly smaller clinics and rural providers, don’t have a pharmacy of their own. That’s where contract pharmacies come in.
A covered entity can sign a written agreement with one or more outside pharmacies, including chain retail pharmacies, to dispense 340B drugs on its behalf. The contract pharmacy must register with HRSA and appear as active in the agency’s tracking system before it can start dispensing discounted medications. You might fill a prescription at a familiar retail pharmacy without realizing it’s being processed through a 340B arrangement.
Contract pharmacy use has expanded dramatically over the years, and it has become one of the most contentious aspects of the program. Covered entities are required to provide oversight of their contract pharmacies and hire an independent firm to audit each contract pharmacy at least once a year. They must also maintain auditable records and report any compliance violations to HRSA. The contract pharmacy arrangement also requires that 340B drugs not be dispensed to Medicaid patients unless the covered entity has a specific agreement with the state Medicaid agency to prevent “duplicate discounts,” where both the 340B discount and a Medicaid rebate are applied to the same prescription.
What This Means for Patients
If you’re a patient at a 340B-covered entity, you may or may not see direct savings at the pharmacy counter. The 340B discount goes to the healthcare organization, not automatically to you. Some covered entities pass along reduced prices, offer sliding-scale fees, or use the savings to fund services like behavioral health programs, transportation assistance, or expanded clinic hours. Others use the revenue to offset the cost of providing uncompensated care.
Because there’s no federal requirement dictating how covered entities spend their 340B savings, the patient experience varies widely. A federally qualified health center might use the revenue to keep prescription costs low for uninsured patients, while a large hospital system might direct it toward general operating expenses. This lack of transparency around how savings are used has been a recurring point of criticism from both lawmakers and the pharmaceutical industry.
Ongoing Legal Disputes
The 340B program has been the subject of significant legal conflict, particularly around contract pharmacies. Several major drug manufacturers have attempted to restrict 340B pricing when drugs are dispensed through contract pharmacies rather than a covered entity’s own pharmacy. They argue the program has expanded far beyond its original scope.
Federal courts have reached different conclusions on the issue. The Third Circuit and D.C. Circuit ruled that the 340B statute limits what the federal government can do to force manufacturers to offer discounts through contract pharmacies. This has effectively allowed some manufacturers to impose restrictions. Meanwhile, the Eighth Circuit upheld an Arkansas state law that prohibited manufacturers from restricting 340B pricing at contract pharmacies, finding the state law wasn’t overridden by federal statute. The split among courts means the legal landscape remains unsettled, and the rules may depend on where a covered entity is located.
Program Oversight and Compliance
HRSA requires all covered entities to go through annual recertification, confirming they still meet eligibility requirements and are complying with program rules. The agency also has authority to audit both covered entities and drug manufacturers, though it does not follow a fixed audit schedule. Covered entities must maintain accurate records at all times in case they’re selected for review.
The compliance burden is significant. Beyond tracking which drugs are purchased at 340B prices and ensuring they go only to eligible outpatients, covered entities must guard against “diversion” (giving 340B drugs to ineligible patients) and “duplicate discounts” (collecting both a 340B price and a Medicaid rebate on the same drug). Violations can result in removal from the program.